About CoVPN
We are dedicated to advancing research to find effective vaccines to prevent COVID-19
Over 700,000 Americans from all backgrounds volunteered with us to discover multiple vaccines during the pandemic and our work continues to protect vulnerable people.
Who We Are
The Coronavirus Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic.
Vaccine Studies
mRNA Vaccines – Moderna’s mRNA-1273 and Pfizer & BioNTech’s Vaccines
Janssen’s Ad26.COV2.S Investigational Vaccine, ENSEMBLE Study
Novavax NVX-CoV2373 Investigational Vaccine Clinical Study
Monoclonal Antibody Studies
Eli Lilly’s LY3819253 Antibody, the BLAZE-2 Study
CoVPN 3502/REGN 2069: Regeneron’s REGEN-COV Antibody Cocktail
Surveillance Studies
Immunolog
CoVPN 5001
HVTN 405/1901
Partners
HIV Vaccine Trials Network
The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.
HIV Prevention Trials Network
The HIV Prevention Trials Network (HPTN) develops and tests the safety and efficacy of non-vaccine interventions designed to prevent the transmission of HIV.
Infectious Disease Clinical Research Consortium
NIAID established the Infectious Diseases Clinical Research Consortium in 2019. It encompasses the Institute’s long-standing Vaccine and Treatment Evaluation Units (VTEUs) and a new leadership group.
AIDS Clinical Trials Group
The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world. These investigators and units serve as the major resource for HIV/AIDS research on treatment and care for persons living with HIV/AIDS.